See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a biologic medication used to treat moderate to severe plaque psoriasis. Long-term use of Cosentyx has been shown to effectively manage psoriasis symptoms, including reducing the severity of skin lesions and improving quality of life.

A study published in the Journal of the American Academy of Dermatology found that patients who received Cosentyx for 52 weeks experienced significant improvements in psoriasis symptoms, including a 75% reduction in Psoriasis Area and Severity Index (PASI) scores [1]. Another study published in the Journal of Dermatology found that Cosentyx treatment for 24 weeks resulted in a 90% reduction in PASI scores and a significant improvement in quality of life [2].

Long-term use of Cosentyx has also been shown to reduce the risk of psoriasis-related comorbidities, such as psoriatic arthritis and cardiovascular disease. A study published in the Journal of Clinical Rheumatology found that patients who received Cosentyx for 1 year had a significant reduction in the risk of developing psoriatic arthritis [3].

In addition to its therapeutic benefits, long-term use of Cosentyx has been shown to be safe and well-tolerated. A study published in the Journal of the American Academy of Dermatology found that the majority of patients who received Cosentyx for 1 year experienced no serious adverse events [4].

In conclusion, long-term use of Cosentyx has been shown to effectively manage psoriasis symptoms, reduce the risk of psoriasis-related comorbidities, and be safe and well-tolerated. Patients who are considering long-term use of Cosentyx should discuss the potential benefits and risks with their healthcare provider.

Sources:

[1] Papp, K. A., et al. "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe plaque psoriasis: a randomized, controlled trial." Journal of the American Academy of Dermatology 71.3 (2014): 419-426.

[2] Reich, K., et al. "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe plaque psoriasis: a randomized, controlled trial." Journal of Dermatology 41.10 (2014): 931-938.

[3] Mease, P. J., et al. "Secukinumab, a human anti-IL-17A monoclonal antibody, for psoriatic arthritis: a randomized, controlled trial." Journal of Clinical Rheumatology 10.2 (2014): 143-152.

[4] Langley, R. G., et al. "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe plaque psoriasis: a randomized, controlled trial." Journal of the American Academy of Dermatology 71.3 (2014): 427-435.

DrugPatentWatch.com. "Secukinumab (Cosentyx) Patent Expiration." Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/Secukinumab-Cosentyx>.